My Personal Therapeutics Announces Funding and Secures Exclusive Mount Sinai School of Medicine Technology License to Revolutionize Personalized Cancer Treatment

LONDON, UK – 12th April 2019 – My Personal Therapeutics, a London based biotechnology company announced today that it has completed technology licensing and secured initial funding to transform cancer care. Investment was led by London based Startup Funding Club and independent international investors. Advances in genomics have led to a push towards “Precision Medicine” in which a single driver mutation in a tumor is identified and then is targeted with a specific drug treatment. The challenge is that most cancer patients have multiple mutations and single drugs aren’t effective. Attempts to drug specific parts of the tumor network generally fail because complex networks rapidly adapt; this is a key reason that patients relapse. As a result, for many cancers the response rates are barely in the double digits. Scientists at the Icahn School of Medicine at Mount Sinai Center for Personalized Cancer Therapeutics (CPCT) in New York (USA) take a revolutionary new approach to cancer therapeutics. My Personal Therapeutics has exclusively licensed the Personal Discovery Process (PDP) technology from Mount Sinai for global commercialization. PDP leverages Big Data to build personalized ‘fruit fly avatars’ that model individual patients at an unprecedented level of complexity (see Figure). Using robotics, thousands of drugs are screened in combinations to identify drug cocktails designed to target the tumor while preserving the patient’s quality of life.